Home / Going-concern warnings / Serina Therapeutics, Inc.
Filed 2026-05-14 路 Form 10-Q 路 Accession 0001708599-26-000035 nano
Price before filing: $1.56 (2026-05-13 close, split/dividend-adjusted)
Market cap at flag: $20.7M (2026-05-14) 路 Latest: $28.2M (2026-10-16)
| Window | SER | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | +22.4% | +1.7% | +20.7% | 2026-06-15 |
| 90 days | +80.8% | +4.3% | +76.4% | 2026-08-12 |
| 180 days | pending | pending | until 2026-11-10 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: 1 insider sold $116K (2 sales)
30 days after: 3 insiders bought $76K (6 purchases)
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2026-03-19 | Moreadith Randall Chief Scientific Officer | Sale | 39,000 | $2.50 | $98K | yes | Form 4 |
| 2026-03-23 | Moreadith Randall Chief Scientific Officer | Sale | 6,500 | $2.86 | $19K | yes | Form 4 |
| 2026-05-14: red flag filed | |||||||
| 2026-05-19 | Marshall Richard Peter Director | Purchase | 12,183 | $1.65 | $20K | no | Form 4 |
| 2026-05-21 | WILSON KAREN J Director | Purchase | 10,000 | $1.77 | $18K | no | Form 4 |
| 2026-05-22 | Venkatesan Jay Director | Purchase | 589 | $1.78 | $1K | no | Form 4 |
| 2026-05-22 | WILSON KAREN J Director | Purchase | 10,000 | $1.93 | $19K | no | Form 4 |
| 2026-06-11 | WILSON KAREN J Director | Purchase | 5,100 | $1.75 | $9K | no | Form 4 |
| 2026-06-12 | WILSON KAREN J Director | Purchase | 5,000 | $1.77 | $9K | no | Form 4 |
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2026-02-13 to 2026-06-13. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"As such, there is substantial doubt about the Company's ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2026-03-31)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
🔔 Get email alerts for this company
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.